In surprising flop, Exelixis' Cabometyx combo with Roche's Tecentriq fails to extend life in liver cancer

Retrieved on: 2021-06-28 14:15:00

Tags for this article:

Click the tags to see associated articles and topics

In surprising flop, Exelixis' Cabometyx combo with Roche's Tecentriq fails to extend life in liver cancer. View article details on hiswai:

Excerpt

The combination of Exelixis' Cabometyx and Roche's Tecentriq failed to outdo Bayer's Nexavar at extending life in front-line liver cancer.

Article found on: www.fiercepharma.com